Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

# oncology

Trending Latest

Mashup Score:13

OncLive

FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer - 1 week

Mashup Score:13

The FDA has approved olaparib (Lynparza) plus abiraterone acetate (Zytiga) and prednisone or prednisolone for the treatment of patients with deleterious or suspected deleterious...

More coverage: #oncology #pcsm
See more from

Mashup Score:13

OncLive

Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS - 4 days

Mashup Score:13

Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent,...

More coverage: #asco2023 #mdssm #oncology
See more from

Mashup Score:12

ascopost.com

De Novo Metastatic Hormone-Sensitive Prostate Cancer – The ASCO Post - 7 days

Mashup Score:12

Transcript Disclaimer: This video transcript has not been proofread or edited and may contain errors. Dr. Alicia Morgans: Hi, and welcome to The ASCO...

More coverage: #oncology #pcsm #prostatecancer
See more from

Mashup Score:12

OncLive

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer - 5 days

Mashup Score:12

Pembrolizumab plus chemotherapy with or without bevacizumab led to a substantial improvement in overall survival vs placebo plus chemotherapy with or without bevacizumab in...

More coverage: #asco2023 #gyncsm #oncology
See more from

Mashup Score:10

ascopost.com

Addition of Olaparib and Durvalumab to Standard of Care May Prolong Progression-Free Survival in Patients With Advanced Ovarian Cancer – The ASCO Post - 3 days

Mashup Score:10

By The ASCO Post Staff Posted: 6/3/2023 10:26:00 AM Last Updated: 6/3/2023 9:45:31 AM Patients with newly diagnosed advanced ovarian cancer without a BRCA...

More coverage: #asco23 #gyncsm #oncology #ovariancancer
See more from

Mashup Score:9

OncLive

NALIRIFOX Elicits Statistically Significant Improvement in OS/PFS in Previously Untreated mPDAC - 5 days

Mashup Score:9

Liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin generated statistically significant and clinically meaningful overall survival and progression-free survival benefits compared with gemcitabine plus nab-paclitaxel in...

More coverage: #asco2023 #asco23 #oncology
See more from

Mashup Score:8

Oncology Nursing News

Mirvetuximab Soravtansine Elicits Practice-Changing Outcomes in Frα+ Platinum-Resistant Ovarian Cancer - 2 days

Mashup Score:8

Mirvetuximab soravtansine demonstrated an overall survival benefit in FRα-high, platinum-resistant ovarian cancer vs investigator’s choice...

More coverage: #asco23 #gyncsm #nursing #oncology
See more from

Mashup Score:8

ascopost.com

Lisa Carey and Dennis Slamon on Early Breast Cancer Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy – The ASCO Post - 1 day

Mashup Score:8

2023 ASCO Annual Meeting Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Dennis J. Slamon, MD, PhD, of...

More coverage: #asco23 #bcsm #breastcancer #oncology
See more from

Mashup Score:7

OncLive

Research on Novel Targets and Potential Risk Factors Drives Improvements in the Management of GI Cancers - 7 days

Mashup Score:7

Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in...

More coverage: #oncology
See more from

Mashup Score:7

ascopost.com

Enrique Grande on Metastatic Urothelial Carcinoma Updated Data From IMvigor130 – The ASCO Post - 6 hours

Mashup Score:7

2023 ASCO Annual Meeting Enrique Grande, MD, of The University of Texas MD Anderson Cancer Center, discusses new findings that show initial responses to...

More coverage: #bladdercancer #blcsm #immunotherapy #oncology
See more from
Load More